Drug Discovery World
OCTOBER 18, 2023
They are smaller, which makes them more suitable for cross-linking, and this size, coupled with their stability and high affinity for platelet receptors, makes them ideal reagents for receptor imaging.” Reagents based on nanobodies will increase our understanding of platelet activation in the laboratory.
Drug Discovery World
OCTOBER 13, 2022
Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 3, 2023
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. To what do you attribute your success? Optimer binders are engineered to overcome these problems.
Drug Discovery World
DECEMBER 15, 2022
Improve delivery: Clinical translation of gene therapy is dependent on the efficient and safe delivery of gene editing tools into cells, and this can occur either ex vivo or in vivo. In vivo approaches involve delivering the gene editing components directly into the patient. In one example, Choi et al.
Drug Discovery World
FEBRUARY 15, 2023
Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers. This continues to be the standard of care.
Drug Discovery World
NOVEMBER 30, 2023
coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. GSK has developed high-throughput mammalian and E.
Drug Discovery World
JULY 18, 2023
Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.
Expert insights. Personalized for you.
52 
Let's personalize your content